Welcome to Neuren
A novel and dynamic biopharmaceutical company developing human therapies for neuroprotection, metabolic disease and growth-related disorders.
Recent announcements
25 November 2009Dr John Holaday joins Neuren Board
18 November 2009
Neuren Arranges up to AU$7.8m in New Funding
17 November 2009
Appendix 3B Shares Nov 2009